Akademik Veri Yönetim Sistemi
Turk Hijyen ve Deneysel Biyoloji Dergisi, cilt.82, sa.4, ss.651-658, 2025 (Scopus, TRDizin)
Objective: Cancer is one of the most significant health problems in both developed and developing countries today. Most of the currently available anticancer drugs can cause severe side effects and toxicities, which negatively affect patients’ quality of life. Therefore, the development of safer and more selective anticancer agents remains one of the primary goals of contemporary oncology research. In recent years, the cytotoxic and antiproliferative effects of various pharmacological agents on different cancer cell lines have been extensively studied. This study aimed to investigate the potential anticancer effects of the Climbazole (CBZ) derivative, Climbazole-alcohol, on different human-derived cancer cell lines (HT-29, MKN28, A549, MDA-MB-231) and a normal control cell line (HEK293) under in vitro conditions. Methods: CBZ was reduced to Climbazole-alcohol according to previously reported procedures, and the structure was confirmed by ¹H-NMR spectroscopy. Human cancer cell lines (HT-29, MKN28, A549, MDA MB-231) and the normal HEK293 cell line were cultured under standard conditions at 37°C in a humidified atmosphere containing 5% CO2.Cells were treated with various concentrations of Climbazole-alcohol for 72 hours. Cytotoxicity was assessed using the MTT assay, and IC50 values were determined using GraphPad Prism software. Results: Climbazole-alcohol induced a mild decrease in cell viability in all tested cell lines but did not exhibit a significant cytotoxic effect. The calculated IC50 values were 179.2 µM for HT-29, 168.1 µM for MKN28, 164.1 µM for A549, 158.6 µM for MDA-MB-231, and 169.8 µM for HEK293. No statistically significant difference was observed between cancer and normal cell lines (p>0.05). Conclusion: Climbazole-alcohol did not display selective anticancer activity within the tested concentration range. The findings indicate that this compound lacks cancer-specific cytotoxicity, suggesting limited potential as an anticancer agent. Future studies should focus on structural modifications or combination therapies to enhance its anticancer properties.